You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,086,010


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,086,010
Title:Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells
Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2\'-deoxyuridine (fdU or foUdR) or a 5-formyl-2\'-deoxyuridine derivative, optionally in combination with 5-hydroxy-2\'-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5-fluoro-2\'-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2\'-deoxyuridine (FdU). Related pharmaceutical compositions are also provided.
Inventor(s): Matsumoto; Yoshihiro (Kasugai, JP), Tomkinson; Alan Edward (Albuquerque, NM), Ide; Hiroshi (Higashi-Hiroshima, JP)
Assignee: STC.UNM (Albuquerque, NM)
Application Number:15/126,777
Patent Claims:1. A method of treating a neoplasm, the method comprising administering to a subject in need thereof a therapeutically effective amount of: (a) 5-formyl-2'-deoxyuridine (fdU) or a 5-formyl-2'-deoxyuridine (fdU) derivative, optionally in combination with 5-hydroxy-2'-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of 5-fluorouracil (5-FU), a 5-fluorouracil (5-FU) prodrug and a 5-FU metabolite.

2. The method of claim 1, wherein: (a) the 5-fluorouracil (5-FU) prodrug is selected from the group consisting of 5-fluoro-2'-deoxyuridine (FdU), 5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine (capecitabine), 13F-1 (a 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO.sub.2) COOCH.sub.3 tripeptide), 1-(2-tetrahydrofuryl)-5-fluorouracil, 3, 5-dioctanoyl 5-fluoro-2-deoxyuridine, UFT (ftorafur (FTO) and uracil), S-1 (ftorafur (FTO) and 5-chloro-2,4-dihydroxypyridine plus potassium oxonate), 5-FA-PAE (5-fluorouracil-1 acetic acid (5-FA) coupled with PEG derivatives by an ester bond), 5-FU-lipid conjugates, hyaluronan-5-fluorouracil conjugate (HA-5-Fu), cholesteryl-hexahydrophthaloyl-5-fluorouracil (CHHP-5-FU)), tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4); and (b) the 5-FU metabolite is fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphophate (FdUTP) or fluorouridine triphophate (FUTP).

3. The method of claim 1, wherein the subject is co-administered 5-formyl-2'-deoxyuridine (fdU) and either 5-FU or 5-fluoro-2'-deoxyuridine (FdU).

4. The method of claim 1, wherein 5-formyl-2'-deoxyuridine (fdU) is in the form of a mixture of .alpha.-anomers and .beta.-anomers.

5. The method of claim 1, wherein 5-formyl-2'-deoxyuridine (fdU) is in the form of a substantially purified .alpha.-anomer.

6. The method of claim 1, wherein 5-formyl-2'-deoxyuridine (fdU) is in the form of a substantially purified .beta.-anomer.

7. The method of claim 1, wherein the sugar group of 5-formyl-2'-deoxyuridine (fdU), 5-formyl-2'-deoxyuridine (fdU) derivative and 5-hydroxy-T-deoxyuridine (hUdR) is halogenated.

8. The method of claim 7, wherein the sugar group of 5-formyl-2'-deoxyuridine (fdU), 5-formyl-2'-deoxyuridine (fdU) derivative and 5-hydroxy-2'-deoxyuridine (hUdR) is halogenated with either chlorine or fluorine.

9. The method of claim 1, wherein 5-formyl-2'-deoxyuridine (fdU) is protected.

10. The method of claim 9, wherein 5-formyl-2'-deoxyuridine (fdU) is protected by converting the 5-formyl-2'-deoxyuridine (fdU) carbonyl group to either an acetal or hydrazide group ex vivo, said acetal and hydrazine group converting in vivo to a carbonyl group.

11. The method of claim 1, wherein the subject is administered concomitantly: (a) 5-formyl-2'-deoxyuridine (fdU), optionally in combination with 5-hydroxy-T-deoxyuridine (hUdR); and (b) 5-fluorouracil (5-FU) and/or 5-fluoro-2'-deoxyuridine (FdU) and/or and pentyl [1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-pyrimid- in-4-yl] carbamate (capecitabine).

12. The method of claim 1, wherein the subject suffers from a cancer.

13. The method of claim 12, wherein at least one additional anti-cancer agent or anti-cancer therapy is co-administered to the subject.

14. The method of claim 13, wherein the subject is treated by an additional therapy and/or therapeutic agent selected from the group consisting of one or more additional chemotherapeutic agents such as paclitaxel and docetaxel, platinum-based antineoplastics, hormonal therapy, proton therapy, cryosurgery, and/or high intensity focused ultrasound (HIFU).

15. The method of claim 1, wherein one or more PARP inhibitors are co-administered to the subject.

16. The method of claim 1, wherein the subject suffers from a cancer selected from the group consisting of colorectal cancer (CRC), breast cancer, ovarian cancer, glioblastoma multiform (GBM), melanoma, lung cancer and a glioma and is co-administered a therapeutically-effective amount of (1) 5-FU, a 5-fluorouracil (FU) prodrug or a 5-FU metabolite and (2) 5-formyl-2'-deoxyuridine (fdU), optionally in combination with 5-hydroxy-2'-deoxyuridine (hUdR).

17. The method of claim 16, wherein the subject is treated concomitantly by radiotherapy and is optionally treated with a radiosensitizer prior to or during radiotherapy.

18. The method of claim 1, wherein the subject suffers from a treatment-resistant cancer selected from the group consisting of metastatic colorectal cancer (mCRC), breast cancer in which BRCA1-deficient cells exhibit decreased sensitivity to PARP inhibitors, ovarian cancer which is resistant to platinum-containing anti-neoplastic drugs, hormone and castration-resistant prostate cancer, metastatic melanoma, drug resistant childhood acute lymphoblastic leukemia (ALL) and radiotherapy-resistant glioblastomas, cervical cancer, esophageal cancer (EC), breast cancers and non-small cell lung cancer.

19. The method of claim 1, wherein the subject suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) and is treated with a therapeutically-effective amount of: (a) (1) 5-FU, a 5-fluorouracil (FU) prodrug or a 5-FU metabolite and (2) 5-formyl-2'-deoxyuridine (fdU), optionally in combination with 5-hydroxy-2'-deoxyuridine (hUdR); and (b) an EGFR-directed treatment.

20. The method of claim 1, wherein the subject suffers from BRCA-associated or refractive breast or ovarian cancer and is co-administered a therapeutically-effective amount of: (a) (1) 5-FU, a 5-fluorouracil (FU) prodrug or a 5-FU metabolite and (2) 5-formyl-2'-deoxyuridine (fdU), optionally in combination with 5-hydroxy-2'-deoxyuridine (hUdR); and (b) one or more additional anti-cancer agents selected from the group consisting of a chemotherapeutic agent, a HER antibody, an antibody directed against a tumor associated antigen, an anti-hormonal compound, a cardioprotectant, a cytokine, an EGFR-targeted drug, an anti-angiogenic agent, a tyrosine kinase inhibitor, a COX inhibitor, a non-steroidal anti-inflammatory drug, a farnesyl transferase inhibitor, an antibody that binds oncofetal protein CA 125, HER2 vaccine, HER targeting therapy, Raf or ras inhibitor, doxorubicin, topotecan, taxane, a dual tyrosine kinase inhibitor, TLK286 and EMD-7200, Rucaparib and a PARP inhibitor.

21. The method of claim 1, wherein the subject suffers from colorectal cancer or mCRC and is co-administered a therapeutically-effective amount of: (a) (1) 5-FU, a 5-fluorouracil (FU) prodrug or a 5-FU metabolite and (2) 5-formyl-2'-deoxyuridine (fdU), optionally in combination with 5-hydroxy-2'-deoxyuridine (hUdR); and (b) at least one additional anti-cancer agent selected from the group consisting of (1) oxaliplatin and/or irinotecan, (2) an anti-VEGF-A antibody, (3) an anti-epidermal growth factor receptor (anti-EGFR) antibody, (4) an anti-angiogenic multi-kinase inhibitor, (5) an anti-angiogenic compound, (6) leucovorin.

22. The method of claim 1, wherein the subject suffers from one or more cancers selected from the group consisting of breast cancer, ovarian cancer, non-small-cell lung cancer and prostate cancer.

23. The method of claim 1, wherein the subject suffers from one or more cancers selected from the group consisting of relapsed or refractory T-cell prolymphocytic leukemia (T-PLL), chronic lymphocytic leukemia (CLL), locally advanced or metastatic colorectal carcinoma (CRC), persistent or recurrent endometrial carcinoma, locally advanced or metastatic triple negative or highly proliferative estrogen receptor positive (ER+) breast cancer and partially platinum-sensitive epithelial ovarian cancer.

24. A pharmaceutical formulation which is useful in the treatment of a neoplasm, the pharmaceutical formulation comprising a therapeutically-effective amount of: (a) one or more active ingredients selected from the group consisting of 5-FU, a 5-fluorouracil (FU) prodrug or a 5-FU metabolite; (b) 5-formyl-2'-deoxyuridine (fdU) or a 5-formyl-2'-deoxyuridine (fdU) derivative, optionally in combination with 5-hydroxy-2'-deoxyuridine (hUdR); and (c) optionally, a pharmaceutically acceptable excipient.

25. The pharmaceutical formulation of claim 24, wherein the pharmaceutical formulation is useful in the treatment of a cancer and comprises one or more additional anti-cancer agents.

26. The pharmaceutical formulation of claim 25, wherein the pharmaceutical formulation comprises one or more PARP inhibitors.

27. The pharmaceutical formulation of claim 25, wherein the pharmaceutical formulation comprises one or more platinum-based antineoplastic drugs.

28. A method of treating a subject who suffers from a malignant tumor, the method comprising inducing programmed necrosis in cancerous tumor cells by co-administering to the subject: (a) 5-formyl-2'-deoxyuridine (fdU) or a 5-formyl-2'-deoxyuridine (fdU) derivative, optionally in combination with 5-hydroxy-2'-deoxyuridine (hUdR); and (b) at least one compound selected from the group consisting of 5-fluorouracil (5-FU), a fluorouracil (5-FU) prodrug and a 5-FU metabolite.

29. The method of claim 1, wherein: (a) the 5-fluorouracil (5-FU) prodrug is selected from the group consisting of 5-fluoro-2'-deoxyuridine (FdU), 5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine (Capecitabine), 13F-1 (a 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO.sub.2) COOCH.sub.3 tripeptide), 1-(2-tetrahydrofuryl)-5-fluorouracil, 3, 5-dioctanoyl 5-fluoro-2-deoxyuridine, UFT (ftorafur (FTO) and uracil), S-1 (ftorafur (FTO) and 5-chloro-2,4-dihydroxypyridine plus potassium oxonate), 5-FA-PAE (5-fluorouracil-1 acetic acid (5-FA) coupled with PEG derivatives via ester bond), 5-FU-lipid conjugates, hyaluronan-5-fluorouracil conjugate (HA-5-Fu), cholesteryl-hexahydrophthaloyl-5-fluorouracil (CHHP-5-FU)), tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4); and (b) the 5-FU metabolite is fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphophate (FdUTP) or fluorouridine triphophate (FUTP).

30. The method of claim 28, wherein 5-formyl-2'-deoxyuridine (fdU) is co-administered to the subject.

31. The method of claim 28, wherein PARP1-dependent necrosis is induced in malignant tumor cells.

32. The method of claim 28, wherein a PARP inhibitor is co-administered to the subject.

33. The method of claim 28, wherein the 5-FU prodrug is 5-fluoro-2'-deoxyuridine (FdU).

34. The method of claim 28, the method further comprising treating the subject with an additional therapy and/or therapeutic agent selected from the group consisting of paclitaxel, docetaxel, a platinum-based antineoplastic, hormonal therapy, proton therapy, cryosurgery, and/or high intensity focused ultrasound (HIFU).

35. The method of claim 28, wherein the tumor is a metastatic colorectal cancer (mCRC) tumor and wherein the subject is co-administered therapeutically-effective amounts of: (a) (1) 5-fluoro-2'-deoxyuridine (FdU) and (2) 5-FU or 5-fluoro-2'-deoxyuridine (FdU); and (b) at least one additional anti-cancer agent selected from the group consisting of (1) oxaliplatin and/or irinotecan, (2) an anti-VEGF-A antibody, (3) an anti-epidermal growth factor receptor (anti-EGFR) antibody, (4) an anti-angiogenic multi-kinase inhibitor, (5) an anti-angiogenic compound, and (6) leucovorin.

36. The method of claim 28, wherein the subject is co-administered therapeutically-effective amounts of: (a) (1) 5-fluoro-2'-deoxyuridine (FdU) and (2) 5-FU or 5-fluoro-2'-deoxyuridine (FdU); and (b) one or more additional anti-cancer agents selected from the group consisting of Regorafenib (BAY 73-4506), bevacizumab, cetuximab, oxaliplatin, irinotecan, leucovorin, MK-4827 and CEP-9722.

37. The method according to claim 14 wherein said additional therapeutic agent is at least one agent selected from group consisting of paclitaxel, docetaxel, cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, tr iplatin, and lipoplatin.

38. The method according to claim 19 wherein said EGFR treatment is the co-administration of cetuximab and panitumumab.

39. The method according to claim 21 wherein said said anti-VEGF-A antibody is bevacizumab, said EGFR antibody is cetuximab or panitumumab, said anti-angiogenic multi-kinase is regorafenib and said anti-angiogenic compound is aflibercept.

40. The method according to claim 34 wherein said platinum based antineoplastic agent is selected from group consising of cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, triplatin, and lipoplatin.

41. The method according to claim 35 wherein said said anti-VEGF-A antibody is bevacizumab, said EGFR antibody is cetuximab or panitumumab, said anti-angiogenic multi-kinase is regorafenib and said anti-angiogenic compound is aflibercept.

Details for Patent 10,086,010

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 ⤷  Try a Trial 2034-03-18
Eli Lilly And Company ERBITUX cetuximab Injection 125084 03/28/2007 ⤷  Try a Trial 2034-03-18
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2034-03-18
Amgen, Inc. VECTIBIX panitumumab Injection 125147 09/27/2006 ⤷  Try a Trial 2034-03-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.